Adam May on $ABVX's blowout data and subsequent stock crash

Abivax posted maybe the best ulcerative colitis data anyone's seen, then crashed 60% on a cancer signal Adam May argues is statistical noise. We dig into whether $ABVX is now a mispriced takeout: the maintenance efficacy that beat Rinvoq, how the scary "seven cancer cases" collapse to two, the blackbox question, the Crohn's skew, and the part two safety data due within weeks. Then a quick look at Nectar (NKTR), its alopecia areata data, and the Eli Lilly lawsuit.This episode is sponsored by AlphaSense, and specifically Andrew's upcoming AI webinar with them: breaking down the modern AI stack for investors with Dave Wang (Wall Street Prompts) and Ben Collins (AlphaSense). Goes live June 25. Register here. Chapters:00:00 Intro and disclosure (long ABVX and NKTR)01:03 Sponsor: AlphaSense AI webinar for investors02:33 The biotech "GOAT" returns03:33 Abivax setup: induction vs maintenance, the stakes06:38 The bar: clinical remission and Rinvoq10:14 Blowout maintenance data, and endoscopic remission that doubles Rinvoq14:23 The data drops, then a 60% crash16:31 The cancer scare, taken apart case by case24:45 Why it's statistical noise: mechanism, clustering, base rates28:50 Adverse-event capture and the phase 2 safety database33:57 Bear case: hasn't the market had time to digest this?38:00 Blackbox or no blackbox, and does it matter at $10040:32 The Crohn's readout and the skew45:36 M&A: timing, the new CCO, what Adam wants them to do47:38 Part two safety data due within weeks54:46 The cash question: secondary vs sale57:49 Nectar: strong data, then an unexplained selloff59:54 The Eli Lilly lawsuit and the jury-trial angle01:03:26 Ox40 read-through and the Q32 Bio overhang01:06:07 Most mispriced pick, targets, and the CEO's Cincor parallel01:12:10 WrapLinks:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/Disclosure: Long ABVX and NKTR